Novel Studies Seek to Optimize HER2+ Breast Cancer Management
The primary end point of DESTINY‑Breast11 is pathologic complete response (pCR) rate, and key secondary end points include event‑free survival (EFS), invasive disease‑free survival (IDFS), and overall survival.
The article discusses recent and ongoing clinical trials exploring antibody‑drug conjugates (ADCs) for HER2‑positive breast cancer, focusing on trials such as DESTINY‑Breast11 (NCT05113251) and CompassHER2 pCR (NCT04266249), and considers how future findings may refine treatment standards and early intervention strategies.
Demonstrating that an ADC–based regimen can achieve high pCR rates may support shifting the standard of care toward less intensive chemotherapy in early HER2‑positive breast cancer, potentially reducing toxicity while maintaining efficacy.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC